Structural Septal Device Relieves Heart Failure Symptoms
By HospiMedica International staff writers Posted on 03 Oct 2018 |
Image: A small interatrial shunt helps relieve heart failure symptoms (Photo courtesy of Corvia Medical).
A novel shunt forms a passage between the left and right atria, enabling the left atrium to decompress at rest and physical activity, lowering left atrial pressure.
The Corvia Medical (Tewksbury, MA, USA) Interatrial Shunt Device (IASD) is an innovative transcatheter implant intended for diastolic heart failure (HF) patients with preserved ejection fraction (HFpEF) or mid-range (HFmrEF) ejection fraction. After creating a small opening in the atrial septum, the IASD implant is deployed, forming a permanent passage between the atria and facilitating continuous and dynamic decompression of the left atrium. As a result, HF symptoms and quality of life are improved and HF hospitalization rates are reduced.
One-year follow-up data of the IASD clinical study, held in 64 patients implanted at 18 centers in eleven countries, demonstrated shunt patency for all participants who received the implant. Study endpoints, as measured by exercise pulmonary capillary wedge pressure (PCWP) reduction, showed a reduction in New York Heart Association (NYHA) class. Procedural safety, assessed by major adverse cardiovascular, cerebral, or renal events (MACCRE), showed that the IASD is also safe. The study was presented at the European Society of Cardiology (ESC) annual congress, held during August 2018 in Munich (Germany).
“The clinical study is of tremendous interest to me, because HFpEF is a clinical problem for which there is no effective therapy,” said co-lead author and study presenter Ted Feldman, MD, of Evanston Hospital (IL, USA). “We've now studied the IASD in several consecutive trials. The early single-arm studies demonstrated that people felt better and their exercise capacity improved. Now, a sham-controlled randomized study conclusively proves the mechanism of action and again suggests clinical efficacy in midterm follow-up.”
HFpEF accounts for approximately 50% of all HF, affecting more than 6.2 million people in the United States and Europe, but treatment options remain limited, consisting mainly of diuretics and fluid balance control. People with HFpEF suffer from difficulty breathing, find simple daily activities tiring (if not impossible), and are frequently hospitalized, with a resultant dramatic reduction in their quality of life. Although the pathophysiology of HFpEF is complex, many of the symptoms are a result of excessive rises in left atrial pressure, in particular during exercise.
Related Links:
Corvia Medical
The Corvia Medical (Tewksbury, MA, USA) Interatrial Shunt Device (IASD) is an innovative transcatheter implant intended for diastolic heart failure (HF) patients with preserved ejection fraction (HFpEF) or mid-range (HFmrEF) ejection fraction. After creating a small opening in the atrial septum, the IASD implant is deployed, forming a permanent passage between the atria and facilitating continuous and dynamic decompression of the left atrium. As a result, HF symptoms and quality of life are improved and HF hospitalization rates are reduced.
One-year follow-up data of the IASD clinical study, held in 64 patients implanted at 18 centers in eleven countries, demonstrated shunt patency for all participants who received the implant. Study endpoints, as measured by exercise pulmonary capillary wedge pressure (PCWP) reduction, showed a reduction in New York Heart Association (NYHA) class. Procedural safety, assessed by major adverse cardiovascular, cerebral, or renal events (MACCRE), showed that the IASD is also safe. The study was presented at the European Society of Cardiology (ESC) annual congress, held during August 2018 in Munich (Germany).
“The clinical study is of tremendous interest to me, because HFpEF is a clinical problem for which there is no effective therapy,” said co-lead author and study presenter Ted Feldman, MD, of Evanston Hospital (IL, USA). “We've now studied the IASD in several consecutive trials. The early single-arm studies demonstrated that people felt better and their exercise capacity improved. Now, a sham-controlled randomized study conclusively proves the mechanism of action and again suggests clinical efficacy in midterm follow-up.”
HFpEF accounts for approximately 50% of all HF, affecting more than 6.2 million people in the United States and Europe, but treatment options remain limited, consisting mainly of diuretics and fluid balance control. People with HFpEF suffer from difficulty breathing, find simple daily activities tiring (if not impossible), and are frequently hospitalized, with a resultant dramatic reduction in their quality of life. Although the pathophysiology of HFpEF is complex, many of the symptoms are a result of excessive rises in left atrial pressure, in particular during exercise.
Related Links:
Corvia Medical
Latest Surgical Techniques News
- Miniaturized Implantable Multi-Sensors Device to Monitor Vessels Health
- Tiny Robots Made Out Of Carbon Could Conduct Colonoscopy, Pelvic Exam or Blood Test
- Miniaturized Ultrasonic Scalpel Enables Faster and Safer Robotic-Assisted Surgery
- AI Assisted Reading Tool for Small Bowel Video Capsule Endoscopy Detects More Lesions
- First-Ever Contact Force Pulsed Field Ablation System to Transform Treatment of Ventricular Arrhythmias
- Caterpillar Robot with Built-In Steering System Crawls Easily Through Loops and Bends
- Tiny Wraparound Electronic Implants to Revolutionize Treatment of Spinal Cord Injuries
- Small, Implantable Cardiac Pump to Help Children Awaiting Heart Transplant
- Gastrointestinal Imaging Capsule a Game-Changer in Esophagus Surveillance and Treatment
- World’s Smallest Laser Probe for Brain Procedures Facilitates Ablation of Full Range of Targets
- Artificial Intelligence Broadens Diagnostic Abilities of Conventional Coronary Angiography
- AI-Powered Surgical Visualization Tool Supports Surgeons' Visual Recognition in Real Time
- Cutting-Edge Robotic Bronchial Endoscopic System Provides Prompt Intervention during Emergencies
- Handheld Device for Fluorescence-Guided Surgery a Game Changer for Removal of High-Grade Glioma Brain Tumors
- Porous Gel Sponge Facilitates Rapid Hemostasis and Wound Healing
- Novel Rigid Endoscope System Enables Deep Tissue Imaging During Surgery